anthony quinn

anthony quinn

SBC-103 and Sanfilippo B

2w ago
SOURCE  

Description

Anthony Quinn, MBChB(MD), PhD, FRCP, chief medical officer and head of research and development at Synagenva Biopharma discusses the drug SBC-103, the orphan drug the company is developing for the treatment of mucopolysaccharidosis IIIB (MPS IIIB, Sanfilippo B). In this video, Dr Quinn is hopeful that their drug will have both peripheral and central affects in helping children with MPS IIIB. SBC-103 is a recombinant form of the natural human NAGLU enzyme. It is an investigational enzyme replacement therapy for MPS IIIB. The orphan designated drug received Fast Track designation by the US Food and Drug Administration (FDA) in January 2015.